Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGN-241622 in presbyopia
NCT04403763Phase 2Terminated
- Sponsor
- AbbVie Inc.
- Start
- Jul 2020
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of AGN-241622 in presbyopia (7 arms), sponsored by AbbVie Inc. Primary endpoints: Number of Participants Experiencing a Treatment Emergent Adverse Event After Single Administration of AGN-241622 up to 2 days and Number of Patients Experiencing a Treatment Emergent Adverse Event After Repeat Administration of AGN-241622 at 14 days. Started Jul 2020; status: terminated.
02
Drugs
AGN-241622
03
Conditions
presbyopia
Beyond the preview
Go deeper on NCT04403763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04403763.